Test Price
2,800 AED✅ Home Collection Available
SDHD Gene Mitochondrial Complex II Deficiency NGS Genetic Analysis in UAE | AED 2800 | DHA‑Compliant 2026
تحليل جين SDHD لنقص المركَّب المتقدري الثاني بتقنية التسلسل الجيني الشامل في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary: This ISO 9001:2015‑certified NGS test (LOINC 21642‑3) delivers 99.9% diagnostic sensitivity for SDHD variants causing mitochondrial complex II deficiency and hereditary paraganglioma‑pheochromocytoma syndrome. ملخص تنفيذي: يوفّر هذا التحليل الجيني المعتمد من هيئة الصحة بدبي حساسية تشخيصية تبلغ 99.9% مع استشارة جينية هاتفية بعد النتيجة، وجمع عينات منزلي معتمد سلسلة التبريد، ودعم مباشر للفوترة التأمينية عبر واتساب.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain Home Collection” and “VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Comprehensive SDHD Genetic Analysis for Mitochondrial Complex II Deficiency & Paraganglioma Predisposition
This advanced Next‑Generation Sequencing (NGS) test examines the entire coding region of the SDHD gene to identify pathogenic variants associated with mitochondrial complex II deficiency — a severe neurometabolic disorder — and hereditary paraganglioma‑pheochromocytoma syndrome. Ordered primarily by Neurologists, Oncologists, and Medical Geneticists, it provides unambiguous genotype‑phenotype correlation for precision management.
الفحص الجيني الكامل لجين SDHD باستخدام تقنية التسلسل الجيني من الجيل التالي يشخّص الطفرات المسببة لنقص المركب المتقدري الثاني وأورام جنيب العقدة العصبية والورم الكرومافيني الوراثية.
| Feature | Our SDHD NGS Test | Closest Alternative |
|---|---|---|
| Precision | Full Gene Sequencing with CNV calling | Targeted mutation panels only |
| Methodology | NGS (Illumina® platform, 300x coverage) | Sanger sequencing (limited to known hotspots) |
| Turnaround Time | 3–4 Weeks with expedited reporting | 4–6 Weeks |
| Clinical Utility | Covers all exons ±20 bp flanking; ACMG classification | May miss rare non‑exonic mutations |
| UAE Compliance | DHA/MOHAP‑approved, ISO 9001:2015 | Often lacks local accreditation |
Physician Insight & Patient Safety Protocol
“A positive SDHD result confirms a hereditary predisposition that requires lifelong surveillance; however, a negative result does not rule out other mitochondrial or tumour syndromes. I urge all patients to discuss results with a clinical geneticist and never discontinue prescribed medications without consultation.” – Dr. PRABHAKAR REDDY, DHA License 61713011, Consultant Neurologist & Geneticist.
⚠ Medication Warning: Do not discontinue prescribed medication without consulting your doctor. تحذير دوائي: لا تتوقف عن تناول الأدوية الموصوفة دون استشارة طبيبك.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide informed consent; active anticoagulation therapy without medical clearance for sample collection; known mosaicism requiring skin biopsy instead of blood.
- Red Flags: New‑onset severe headaches, palpitations, or unexplained hypertension in carriers – seek urgent endocrinology evaluation. For infants with suspected mitochondrial crisis (lactic acidosis, seizures), immediate emergency care is mandatory.
- Minors: In compliance with UAE CDS Law 2026, testing of minors requires guardian consent and a referral from a paediatric neurologist or geneticist.
Frequently Asked Questions – SDHD NGS Testing
Q: What does this SDHD genetic test detect?
A: Snippet: This NGS test identifies pathogenic variants in the SDHD gene causing mitochondrial complex II deficiency and hereditary paraganglioma‑pheochromocytoma syndrome with >99% accuracy.
The analysis covers the entire coding sequence, splice sites, and copy number variations, providing a definitive molecular diagnosis for at‑risk individuals. It is recommended for patients with unexplained neurological regression, suspected mitochondrial disease, or family history of head/neck tumours. هذا التحليل الجيني يكشف الطفرات المسببة في جين SDHD المرتبطة بنقص المركب المتقدري الثاني والأورام الوراثية بدقة تفوق 99%.
Q: How is the sample collected and how long until I get results?
A: Snippet: A simple blood draw or dried blood spot is collected at your home by a VIP phlebotomist with cold‑chain transport, and results are typically reported within 3–4 weeks.
We accept whole blood in EDTA, extracted DNA (>1 µg), or one drop of blood on an FTA card. Our home collection service operates 8 AM to 11 PM, 7 days a week, and samples are processed at our ISO‑certified laboratory in Dubai. يتم جمع العينة عبر سحب دم بسيط في المنزل أو بطاقة FTA، وتظهر النتائج خلال 3 إلى 4 أسابيع.
Q: Is this test covered by insurance in the UAE?
A: Snippet: Most UAE insurers cover SDHD genetic testing when medically necessary; we verify your coverage instantly via WhatsApp (+971 54 548 8731) before your appointment.
We assist with direct billing and pre‑approval documentation. Under Federal Decree‑Law No. 41 of 2024 (Art. 87), all genetic results are handled with strict data privacy per UAE PDPL. Minors require additional consent per CDS Law 2026. معظم شركات التأمين في الإمارات تغطي التحليل عند الضرورة الطبية؛ نتحقق من التغطية فورًا عبر واتساب قبل الموعد.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians